dd11-1108 foa final 5.19.11.doc

Table of Contents

Part 1. Overview Information Part 2. Full Text of the Announcement Section I. Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV. Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII. Agency Contacts Section VIII. Other Information

PART 1. OVERVIEW INFORMATION

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Federal Agency Name: Federal Centers for Disease Control and Prevention (CDC) Funding Opportunity Title: Blood Safety Surveillance among People with Blood Disorders Announcement Type:

· New – Type 1

Agency Funding Opportunity Number: CDC-RFA-DD11-1108 Catalog of Federal Domestic Assistance Number: 93.184 Key Dates:

Letter of Intent Deadline Date: June 17, 2011 Application Deadline Date: July 18, 2011, 5:00pm Eastern Standard Time Measurable outcomes of the program will be in alignment with one (or more) of the following performance goal(s) for the National Center on Birth Defects and Developmental Disabilities (NCBDDD), Division of Blood Disorders (DBD): 1) Prevent and Reduce Complications Experienced by Persons with Certain Blood Disorders, and 2) Improve the Health and Development of All People with Disabilities or Potentially Disabling Conditions.

This announcement is only for non-research activities supported by CDC. If research is proposed, the application will not be reviewed. For the definition of research, please see the CDC Web site at the following Internet address:

http://www.cdc.gov/od/science/integrity/docs/cdc-policy-distinguishing-public-health-research-nonresearch.pdf

PART 2. FULL TEXT

I .FUNDING OPPORTUNITY DESCRIPTION

Statutory Authority This program is authorized under Sections 311, 301(a) and 317 (C) of the Public Health Service Act [42 U.S.C. Sections 243, 241a and 247b-4] as amended.

Background Blood transfusions are the foundation of care for patients with severe thalassemia and play a major role in the care of patients with Sickle Cell Disease (SCD) and Diamond Blackfan Anemia (DBA). Consequently, transfusion-related complications can become a major source of morbidity for this patient population. Because there is no natural way for the body to eliminate iron, the iron in the transfused blood cells builds up and becomes toxic to tissues and organs, particularly the liver and heart. Iron overload is a severe complication of transfusions that can result in early death from organ failure. Frequent blood transfusions also expose these populations to infectious agents that may be transmitted through blood. Although blood donors are screened for a number of known infectious diseases, it is possible that new infectious agents or those previously not recognized as blood transmissible would be missed by this screening.

Since 1998, DBD of the CDC has been assisting the nation’s more than 130 federally supported hemophilia treatment centers (HTCs) with blood product safety monitoring through the surveillance system called the Universal Data Collection (UDC) Project. CDC also established the Thalassemia Data and Blood Specimen Collection System in 2004 for the early detection of known and emerging infections that might be transmitted through blood transfusion. This system was modeled after the UDC program, however, it focuses on patients receiving care at seven CDC-funded Thalassemia Treatment Centers (TTCs). Participants in both systems provide blood specimens annually that are tested for the presence of hepatitis and HIV. TTC participants are additionally tested for exposure to West Nile Virus.

The risk of transmitting infectious diseases through blood transfusion has been greatly reduced, primarily as a result of increased vigilance in donor screening and the increasing sensitivity of laboratory screening tests. Nevertheless, transfusion transmission of viruses can still occur when a donor presents for donation in the incubation phase of an illness. In addition, there has been an increase in transfusion-transmitted infections with emerging pathogens such as Babesia app., Dengue, and Chagas. Currently, with the exception of bacterial contamination of platelets, the most substantial risks of blood transfusion-related mortality are non-infectious complications (e.g., transfusion-related acute lung injury [TRALI]), acute hemolytic transfusion reaction, and subsequent iron-overload from repeated transfusions). Additionally, patients with rare blood phenotypes are at higher risk for alloimmunization which increases the risk of adverse transfusion events.

Purpose

The purpose of the program is to provide support and financial assistance through CDC cooperative agreements for non-research activities to help ensure the safety of the nation’s blood supply and meet the shifting priorities of blood safety within heavily transfused patient populations. Awardees will utilize existing blood safety infrastructure and work collaboratively with appropriate patient networks to develop, implement, and evaluate the Blood Safety Surveillance for Transfused Population project to the benefit of these patient populations and to the benefit of the general public to the extent awardee activities may prevent emerging infectious agents from infiltrating the nation’s blood supply. The specimen and data collection obtained from this surveillance project will provide data to describe the epidemiologic characteristics of people with blood disorders who receive at least one therapeutic blood transfusion annually.

Outcomes for this surveillance project include:

1) A better understanding of the risks related to transfusion complications and infectious transmissions

2) An annual laboratory analysis of specimens to determine the burden and location of transfusion-transmitted emerging pathogens

3) A better understanding of rare blood types and blood banking practices

4) Monitoring the rates of transfusion-related complications

5) Development of interventions to prevent the complications of chronic transfusion

CDC’s mission is “to promote health and quality of life by preventing and controlling disease, injury, and disability.” One of the many strategies that CDC employs to accomplish this goal includes “monitoring health” through the use of public health surveillance. Disease specific surveillance systems are critical for the accomplishment of this and other objectives that support CDC’s mission. Consistent with CDC’s mission, CDC has identified four overarching Health Protection Goals. This program is most closely aligned with CDC’s Health Protection Goal of “Healthy People in Every Stage of Life.” Surveillance such as this will help CDC determine ways to achieve optimal lifespan and best possible quality of life across the lifespan for individuals with hemoglobinopathies.

This program addresses the “Healthy People 2020” focus area of Blood Disorders and Blood Safety to prevent adverse transfusion events.

Program Implementation Recipient Activities

· Enroll patients with a blood disorder diagnosis (who receive at least one therapeutic transfusion a year related to diagnosis) into the surveillance for repeated, longitudinal collection of patient-level data on certain characteristics including (but not limited to): demographics, diagnosis, number of transfusions, treatment type, vaccination status, infection status; as well as a blood specimens for screening of blood-borne pathogens, and for storage for screening for adverse transfusion outcomes and pathogens identified in the future;

· Obtain authorization from patients to enroll them in the surveillance and collect and use their information and blood specimens

· Work with the coordinating site to submit blood specimens to the CDC Serum Bank biorepository that will be housed in the in Lawrenceville, Georgia, to be used collaboratively for investigations related emerging pathogens and infectious outbreaks – the CDC serum bank is being recommended due to cost considerations that benefit the general public and quantified safety standards that adhere to acceptable standards.

· Interact with coordinating site that will be responsible for logistics related to the supplies and equipment for collecting, processing, storing and shipping blood specimens

· Communicate and cooperate with the coordinating site to accomplish data reporting, quality control and adherence to standard operating procedure for the collection of data and blood specimens;

· Maintain the confidentiality of the study data in accordance with all applicable laws and regulations.

· Work collaboratively to perform routine data queries for quality assurance

· Respond to data quality queries from CDC or the coordinating site in a timely manner

· Participate in conference calls and an annual face-to-face meeting with CDC.

· Analyze data, and author reports collaboratively with CDC

· Cooperate with local public health officials in the event of an disease outbreak and/or investigation In a cooperative agreement, CDC staff is substantially involved in the program activities, above and beyond routine grant monitoring.

CDC activities

· Provide advisory technical assistance such as defining minimum data elements

· Establish a coordinating site that will provide information and support for logistics related to informatics, data, and specimen collection.

· Develop and provide data collection tools for surveillance.

· Conduct laboratory testing and maintain a bio-specimen repository for future outbreak investigations.

· Facilitating the communication/coordination among awardees regarding standardization of procedures and tools to improve the efficiency of activities.

· Convene awardees to support collaboration and shared learning.

· Assist in performing data analysis and/or quality assurance verification.

· Maintain the centralized database and assist with data dissemination.

· Assist with evaluation of the pilot project.

· Serve as a resource for sharing data, templates, and other information.

II. AWARD INFORMATION

Type of Award: Cooperative Agreement. CDC’s involvement in this program is listed in the Activities Section above.

Award Mechanism: U50 Fiscal Year Funds: 2011 Approximate Current Fiscal Year Funding: $ 1,500,000

Approximate Total Project Period Funding: $ 3,000,000 (This amount is an estimate, and is subject to availability of funds and includes direct and indirect costs.)

Approximate Number of Awards: 10 Approximate Average Award: $ 150,000 (This amount is for the first 12-month budget period and includes direct and indirect costs.)

Floor of Individual Award Range: None Ceiling of Individual Award Range: $ 200,000 (This ceiling is for the first 12-month budget period and includes direct and indirect cost. Subject to availability of funds.)

Anticipated Award Date: 9/30/2011 Budget Period Length: 12 months; 9/30/2011 – 9/29/2012 Project Period Length: 2 years; 9/30/2011 – 9/29/2013 Throughout the project period, CDC’s commitment to continuation of awards will be conditioned on the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports), and the determination that continued funding is in the best interest of the Federal government.

III. ELIGIBILITY INFORMATION

Eligible Applicants Eligible applicants that can apply for this funding opportunity are listed below:

· Nonprofit with 501C3 IRS status (other than institution of higher education)

· Nonprofit without 501C3 IRS status (other than institution of higher education)

· For-profit organizations (other than small business)

· Small, minority, and women-owned businesses

· Universities

· Colleges

· Research institutions

· Hospitals

· Community-based organizations

· Faith-based organizations

· Federally recognized or state-recognized American Indian/Alaska Native tribal governments

· American Indian/Alaska native tribally designated organizations

· Alaska Native health corporations

· Urban Indian health organizations

· Tribal epidemiology centers

· State and local governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau)

· Political subdivisions of States (in consultation with States)

· Non-domestic (non-U.S.) entity

· Other (specify) A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a bona fide agent of a state or local government, a legal, binding agreement from the state or local government as documentation of the status is required. Attach with “Other Attachment Forms” when submitting via www.grants.gov.

Required Registrations

Registering your organization through www.Grants.gov, the official agency-wide E-grant website, is the first step in submitting an application online. Registration information is located on the “Get Registered” screen of www.Grants.gov. Please visit www.Grants.gov at least 30 days prior to submitting your application to familiarize yourself with the registration and submission processes. The “one-time” registration process will take three to five days to complete. However, the Grants.gov registration process also requires that you register your organization with the Central Contractor Registry (CCR). The CCR registration can require an additional one to two days to complete. You are required to maintain a current registration in CCR.

Central Contractor Registration and Universal Identifier Requirements

All applicant organizations must obtain a DUN and Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the Universal Identifier when applying for Federal grants or cooperative agreements. The DUNS number is a nine-digit number assigned by Dun and Bradstreet Information Services. An AOR should be consulted to determine the appropriate number. If the organization does not have a DUNS number, an AOR should complete the US D&B D-U-N-S Number Request Form or contact Dun and Bradstreet by telephone directly at 1-866-705-5711 (toll-free) to obtain one. A DUNS number will be provided immediately by telephone at no charge. Note this is an organizational number. Individual Program Directors/Principal Investigators do not need to register for a DUNS number.

Additionally, all applicant organizations must register in the Central Contractor Registry (CCR) and maintain the registration with current information at all times during which it has an application under consideration for funding by CDC and, if an award is made, until a final financial report is submitted or the final payment is received, whichever is later. CCR is the primary registrant database for the Federal government and is the repository into which an entity must provide information required for the conduct of business as a recipient. Additional information about registration procedures may be found at the CCR internet site at www.ccr.gov.

If an award is granted, the grantee organization must notify potential sub-recipients that no organization may receive a subaward under the grant unless the organization has provided its DUNS number to the grantee organization.

Cost Sharing or Matching

Cost sharing or matching funds are not required for this program.

Other

If a funding amount greater than the ceiling of the award range is requested, the application will be considered non-responsive and will not be entered into the review process. The applicant will be notified that the application did not meet the eligibility requirements.

Special Requirements:

· Applicants must demonstrate having access to at least 250 patients receiving at least one therapeutic transfusion per year as a result of a blood disorder diagnosis.

· Applicants must demonstrate the ability to obtain vaccination information and blood samples for enrollees according to project protocol.

Note: Title 2 of the United States Code Section 1611 states that an organization described in Section 501(c)(4) of the Internal Revenue Code that engages in lobbying activities is not eligible to receive Federal funds constituting a grant, loan, or an award.

Maintenance of Effort is not required for this program IV. Application and Submission Information Applicants must download the SF424 (R&R) application package associated with this funding opportunity from Grants.gov. If access to the Internet is not available or if the applicant encounters difficulty in accessing the forms on-line, contact the HHS/CDC Procurement and Grant Office Technical Information Management Section (PGO TIMS) staff at (770) 488-2700 for further instruction. CDC Telecommunications for the hearing impaired or disabled is available at: TTY 1-888-232-6348.

If the applicant encounters technical difficulties with Grants.gov, the applicant should contact Grants.gov Customer Service. The Grants.gov Contact Center is available 24 hours a day, 7 days a week, with the exception of all Federal Holidays. The Contact Center provides customer service to the applicant community. The extended hours will provide applicants support around the clock, ensuring the best possible customer service is received any time it’s needed. You can reach the Grants.gov Support Center at 1-800-518-4726 or by email at support@grants.gov. Submissions sent by e-mail, fax, CD’s or thumb drives of applications will not be accepted.

Content and Form of Application Submission

CDC Assurances and Certifications can be found on the CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/grants/foamain.shtm Letter of Intent (LOI):

Prospective applicants are asked to submit a letter of intent that includes the following information:

· Name, address, and telephone number of the Principal Investigator/Project Director.

· Participating institutions.

· Number and title of this funding opportunity.

· Descriptive title of proposed project.

LOIs must be received no later than the date indicated in Part I entitled “Key Dates”.

Submit the LOI by express mail, delivery service, fax, or E-mail to:

Sean Trimble, Project Officer Centers for Disease Control and Prevention

National Center on Birth Defects and Developmental Disabilities

Division of Blood Disorders 1825 Century Boulevard – MS E-64

Atlanta, GA 30345 Telephone: 404-498-0184

Email: strimble@cdc.gov Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows CDC Program staff to estimate and plan the review of submitted applications. LOIs should be provided not later than by the date indicated in the Section I entitled “Authorization and Intent”.

A Project Abstract must be completed in the Grants.gov application forms. The Project Abstract must contain a summary of the proposed activity suitable for dissemination to the public. It should be a self-contained description of the project and should contain a statement of objectives and methods to be employed. It should be informative to other persons working in the same or related fields and insofar as possible understandable to a technically literate lay reader. This abstract must not include any proprietary/confidential information.

A Project Narrative must be submitted with the application forms. The project narrative must be uploaded in a PDF file format when submitting via Grants.gov. The narrative must be submitted in the following format:

· Maximum number of pages: 25. If your narrative exceeds the page limit, only the first pages which are within the page limit will be reviewed.

· Font size: 12 point unreduced, Times New Roman

· Double spaced

· Page margin size: One inch

· Number all narrative pages; not to exceed the maximum number of pages.

The narrative should address activities to be conducted over the entire project period and must include the following items in the order listed:

1. Understanding of the Public Health Burden and Impact

· Understanding of the need for this program and the planned activities within the target community

· Clear, concise descriptions and understanding of the requirements, objectives, and purpose of this FOA

· Description of the current number of individuals with Sickle Cell Disease and Thalassemia

· Current number of patients who receive at least one therapeutic transfusion annually related to a blood disorders diagnosis

2. Plan

· Plan to carry out the proposed objectives

· Complete and comprehensive plan for the entire project period

· Reasonable and achievable timeline to complete the activities in the specified project period

· Description of ability to begin immediate implementation of the activities

· Document legal authority to obtain data and blood specimens Additional information may be included in the application appendices. The appendices will not be counted toward the narrative page limit. This additional information includes:

· Budget (SF 424A) and Budget Narrative (Reviewed, but not scored): provide a detailed budget which identifies and describes the basis for the anticipated costs for personnel, fringe benefits, travel, supplies, equipment, contractual, consultants, indirect, and other items.

· Curricula Vitae/Resumes

· Legal authority to obtain surveillance data

· Letters of Support

· Organizational Charts

Additional information submitted via Grants.gov should be uploaded in a PDF file format, and should be named:

· Appendix 1 - Curricula Vitae/Resumes

· Appendix 2 - Letters of Support, etc.

· Appendix 3 -. Organizational Charts

No more than 20 attachments should be uploaded per application.

Additional requirements for additional documentation with the application are listed in Section VII. Award Administration Information subsection entitled “Administrative and National Policy Requirements.”

Submission Dates and Times This announcement is the definitive guide on LOI and application content, submission, and deadline. It supersedes information provided in the application instructions. If the application submission does not meet the deadline published herein, it will not be eligible for review and the applicant will be notified the application did not meet the submission requirements.

Letter of Intent (LOI) Deadline Date: June 17, 2011 Application Deadline Date: July 18, 2011, 5:00pm Eastern Standard Time Intergovernmental Review The application is subject to Intergovernmental Review of Federal Programs, as governed by Executive Order (EO) 12372. This order sets up a system for state and local governmental review of proposed federal assistance applications. Contact the state single point of contact (SPOC) as early as possible to alert the SPOC to prospective applications and to receive instructions on the State’s process. Visit the following Web address to get the current SPOC list: http://www.whitehouse.gov/omb/grants_spoc/.

Funding Restrictions Restrictions, which must be taken into account while writing the budget, are as follows:

· Recipients may not use funds for research.

· Recipients may not use funds for clinical care.

· Recipients may only expend funds for reasonable program purposes, including personnel, travel, supplies, and services, such as contractual.

· Awardees may not generally use HHS/CDC/ATSDR funding for the purchase of furniture or equipment. Any such proposed spending must be identified in the budget.

· The direct and primary recipient in a cooperative agreement program must perform a substantial role in carrying out project objectives and not merely serve as a conduit for an award to another party or provider who is ineligible.

· Reimbursement of pre-award costs is not allowed.

Other Submission Requirements Application Submission Submit the application electronically by using the forms and instructions posted for this funding opportunity on www.Grants.gov. If access to the Internet is not available or if the applicant encounters difficulty in accessing the forms on-line, contact the HHS/CDC Procurement and Grant Office Technical Information Management Section (PGO TIMS) staff at (770) 488-2700 for further instruction.

Note: Application submission is not concluded until successful completion of the validation process. After submission of your application package, applicants will receive a “submission receipt” email generated by Grants.gov. Grants.gov will then generate a second e-mail message to applicants which will either validate or reject their submitted application package. This validation process may take as long as two (2) business days. Applicants are strongly encouraged check the status of their application to ensure submission of their application package is complete and no submission errors exists. To guarantee that you comply with the application deadline published in the Funding Opportunity Announcement, applicants are also strongly encouraged to allocate additional days prior to the published deadline to file their application. Non-validated applications will not be accepted after the published application deadline date.

In the event that you do not receive a “validation” email within two (2) business days of application submission, please contact Grants.gov. Refer to the email message generated at the time of application submission for instructions on how to track your application or the Application User Guide, Version 3.0 page 57.

Electronic Submission of Application Applications must be submitted electronically at www.Grants.gov. Electronic applications will be considered as having met the deadline if the application has been successfully made available to CDC for processing from Grants.gov on the deadline date. The application package can be downloaded from www.Grants.gov. Applicants can complete the application package off-line, and then upload and submit the application via the Grants.gov Web site. The applicant must submit all application attachments using a PDF file format when submitting via Grants.gov. Directions for creating PDF files can be found on the Grants.gov Web site. Use of file formats other than PDF may result in the file being unreadable by staff.

Applications submitted through Grants.gov (http://www.grants.gov), are electronically time/date stamped and assigned a tracking number. The AOR will receive an e-mail notice of receipt when Grants.gov receives the application. The tracking number serves to document submission and initiate the electronic validation process before the application is made available to CDC for processing.

If the applicant encounters technical difficulties with Grants.gov, the applicant should contact Grants.gov Customer Service. The Grants.gov Contact Center is available 24 hours a day, 7 days a week, with the exception of all Federal Holidays. The Contact Center provides customer service to the applicant community. The extended hours will provide applicants support around the clock, ensuring the best possible customer service is received any time it’s needed. You can reach the Grants.gov Support Center at 1-800-518-4726 or by email at support@grants.gov. Submissions sent by e-mail, fax, CD’s or thumb drives of applications will not be accepted.

Organizations that encounter technical difficulties in using www.Grants.gov to submit their application must attempt to overcome those difficulties by contacting the Grants.gov Support Center (1-800-518-4726, support@grants.gov). After consulting with the Grants.gov Support Center, if the technical difficulties remain unresolved and electronic submission is not possible to meet the established deadline, organizations may submit a request prior to the application deadline by email to GMO/GMS for permission to submit a paper application. An organization's request for permission must: (a) include the Grants.gov case number assigned to the inquiry, (b) describe the difficulties that prevent electronic submission and the efforts taken with the Grants.gov Support Center (c) be submitted to the GMO/GMS at least 3 calendar days prior to the application deadline. Paper applications submitted without prior approval will not be considered.

If a paper application is authorized, the applicant will receive instructions from PGO TIMS to submit the original and two hard copies of the application by mail or express delivery service.

V. Application Review Information Eligible applicants are required to provide measures of effectiveness that will demonstrate the accomplishment of the various identified objectives of the DD11-1108. Measures of effectiveness must relate to the performance goals stated in the “Purpose” section of this announcement. Measures of effectiveness must be objective, quantitative and measure the intended outcome of the proposed program. The measures of effectiveness must be included in the application and will be an element of the evaluation of the submitted application.

Criteria

Eligible applications will be evaluated against the following criteria:

1. Plan (30 Points) Is the plan adequate to carry out the proposed objectives? How complete and comprehensive is the plan for the entire project period? Does the plan include quantitative process and outcome measures?

2. Methods (30 Points) Are the proposed methods feasible? To what extent will they accomplish the program goals?

3. Personnel (20 Points) Do the staff members have appropriate experience? Are the staff roles clearly defined? Does the staff have legal authority to carry out the proposed objectives? As described, will the staff be sufficient to accomplish the program goals?

4. Need (20 Points) To what extent does the applicant justify the need for this program within the target community?

Budget (SF 424A) and Budget Narrative (Reviewed, but not scored) The budget is not scored but applicants should consider the following in development of the budget. Is the itemized budget for conducting the project, and justification reasonable and consistent with stated objectives and planned program activities?

If the applicants requests indirect costs in the budget, a copy of the indirect cost rate agreement is required. If the indirect cost rate is a provisional rate, the agreement should be less than 12 months of age. The indirect cost rate agreement should be uploaded as a PDF file with “Other Attachment Forms” when submitting via Grants.gov.

The applicant can obtain guidance for completing a detailed justified budget on the CDC website, at the following Internet address:

http://www.cdc.gov/od/pgo/funding/budgetguide.htm.

Review and Selection Process

Review

All eligible applications will be initially reviewed for completeness by the Procurement and Grants Office (PGO) staff. In addition, eligible applications will be jointly reviewed for responsiveness by National Center on Birth Defects and Developmental Disabilities and PGO. Incomplete applications and applications that are non-responsive to the eligibility criteria will not advance through the review process. Applicants will be notified the application did not meet eligibility and/or published submission requirements.

An objective review panel will evaluate complete and responsive applications according to the criteria listed in Section V. Application Review Information, subsection entitled “Criteria”. The objective review process will follow the policy requirements as stated in the GPD 2.04 at http://198.102.218.46/doc/gpd204.doc. The objective review panel will consist of CDC employees outside of the funding division who will be randomly assigned applications to review and score.

Selection

Applications will be funded in order by score and rank determined by the review panel.

VI. Award Administration Information Award Notices

Successful applicants will receive a Notice of Award (NoA) from the CDC Procurement and Grants Office. The NoA shall be the only binding, authorizing document between the recipient and CDC. The NoA will be signed by an authorized Grants Management Officer and e-mailed to the program director. A hard copy of the NoA will be mailed to the recipient fiscal officer identified in the application.

Any application awarded in response to this FOA will be subject to the DUNS, CCR Registration and Transparency Act requirements.

Unsuccessful applicants will receive notification of the results of the application review by mail.

Administrative and National Policy Requirements

Successful applicants must comply with the administrative requirements outlined in 45 Code of Federal Regulations (CFR) Part 74 or Part 92, as appropriate.

The following additional requirements apply to this project:

● AR-7

Executive Order 12372

· AR-9

Paperwork Reduction Act Requirements

· AR-10

Smoke-Free Workplace Requirements

· AR-11

Healthy People 2020

· AR-12

Lobbying Restrictions

· AR-13

Prohibition on Use of CDC Funds for Certain Gun Control

Activities

· AR-14

Accounting System Requirements

· AR-15

Proof of Non-Profit Status

· AR-21

Small, Minority, and Women-Owned Business

· AR-23

States and Faith-Based Organizations

· AR-24

Health Insurance Portability and Accountability Act Requirements

· AR-25

Release and Sharing of Data

· AR-26

National Historic Preservation Act of 1966

(Public Law 89-665, 80 Stat. 915)

· AR-27

Conference Disclaimer and Use of Logos

· AR-29

Compliance with E.O. 13513 Federal Leadership on Reducing Text Messaging While Driving, October 1, 2009 Additional information on the requirements can be found on the CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/Addtl_Reqmnts.htm.

For more information on the Code of Federal Regulations, see the National Archives and Records Administration at the following Internet address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html Reporting

Federal Funding Accountability And Transparency Act Of 2006 (FFATA): Public Law 109-282, the Federal Funding Accountability and Transparency Act of 2006 as amended (FFATA), requires full disclosure of all entities and organizations receiving Federal funds including grants, contracts, loans and other assistance and payments through a single publicly accessible Web site, USASpending.gov. The Web site includes information on each Federal financial assistance award and contract over $25,000, including such information as:

1. The name of the entity receiving the award

2. The amount of the award

3. Information on the award including transaction type, funding agency, etc.

4. The location of the entity receiving the award

5. A unique identifier of the entity receiving the award; and

6. Names and compensation of highly-compensated officers (as applicable)

Compliance with this law is primarily the responsibility of the Federal agency. However, two elements of the law require information to be collected and reported by recipients: 1) information on executive compensation when not already reported through the Central Contractor Registry; and 2) similar information on all subawards/contracts/consortiums over $25,000.

For the full text of the requirements under the Federal Funding Accountability and Transparency Act of 2006, please review the following website:

http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=109_cong_bills&docid=f:s2590enr.txt.pdf

Each funded applicant must provide CDC with an annual Interim Progress Report submitted via www.grants.gov:

1. The interim progress report is due no less than 90 days before the end of the budget period. The Interim Progress Report will serve as the non-competing continuation application, and must contain the following elements:

a. Standard Form (“SF”) 424S Form

b. SF-424A Budget Information-Non-Construction Programs

c. Budget Narrative

d. Indirect Cost Rate Agreement

e. Project Narrative

Additionally, funded applicants must provide CDC with an original, plus two hard copies of the following reports:

2. Progress reports are due 90 before the end of the budget period.

3. Annual progress report, due 90 days after the end of the budget period.

4. Financial Status Report* (SF 269) are due 90 days after the end of the budget period.

5. Final performance and Financial Status Reports*, no more than 90 days after the end of the project period.

*Disclaimer: As of February 1, 2011, current Financial Status Report (FSR) requirements will be obsolete. Existing practices will be updated to reflect changes for implementation of the new Federal Financial Reporting (FFR) requirements.

The reports must be submitted to the attention of the Grants Management Specialist listed in the Section VII below entitled “Agency Contacts”.

VII. Agency Contacts CDC encourages inquiries concerning this announcement.

For programmatic technical assistance, contact:

Sean Trimble, Project Officer

Department of Health and Human Services

Centers for Disease Control and Prevention

1825 Century Blvd. E-64

Atlanta, GA 30345

Telephone: 404-498-0184

E-mail: Strimble@cdc.gov For financial, grants management, or budget assistance, contact:

Shicann Phillips, Grants Management Specialist

CDC Procurement and Grants Office

2920 Brandywine Road, MS E09

Atlanta, GA 30341

Telephone: 770-488-2615

E-mail:SPhillips2@cdc.gov For assistance with submission difficulties, contact:

Grants.gov Contact Center Phone: 1-800-518-4726.

Hours of Operation: 24 hours a day, 7 days a week. Closed on Federal holidays.

For submission questions, contact:

Technical Information Management Section

CDC Procurement and Grants Office

2920 Brandywine Road, MS E-14

Atlanta, GA 30341

Telephone: 770-488-2700

Email:

pgotim@cdc.gov CDC Telecommunications for the hearing impaired or disabled is available at:

TTY 1-888-232-6348

VIII. Other Information For additional information on reporting requirements, visit the CDC website at: http://www.cdc.gov/od/pgo/funding/grants/additional_req.shtm.

Other CDC funding opportunity announcements can be found at www.grants.gov.

PAGE